http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2015131655-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_42d09f1d32f6494531c696ea59219b0d |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-352 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-352 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00 |
| filingDate | 2015-01-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a5b5ca498112aaa9d7c3e84fd427d336 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_735473738a0dd2fb274eabe57bbbb6e0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_37b4b84c7dd274363854e3966e00c734 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f04851258e599d55519b7a8c2ec3fbae http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6c08233ef3ecec0ab6736decde9e7ed0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e809ca2b11d0c3d23c3e07e3e35609b6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_387b939e854c726f1dc8068ce8f17208 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cb8a2f34e1f3548596092481bd0f9478 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_23187e3c979873451280a344ca75a174 |
| publicationDate | 2015-09-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2015131655-A1 |
| titleOfInvention | Use of fsk in preventing and treating chronic obstructive pulmonary disease |
| abstract | Provided in the invention is a novel use of the compound forskolin (FSK) in preventing and treating chronic obstructive pulmonary disease (COPD). The FSK can be independently used as an effective component for drug use or health-care use, and also can be prepared into tablets, buccal tablets, capsules, granules, oral solutions, injections, aerosols, emplastrum and the like with other components free from repulsive interactions. The present invention adopts administration methods such as FSK oral intragastric administration and intraperitoneal injections and the like, and experimental research has been performed on a cigarette smoke inhalation induction mouse COPD model and an elastase induction mouse COPD model to prove that FSK has an obvious preventative/treatment effect on the cigarette smoke inhalation induction COPD and the elastase induction COPD. Furthermore, the acute toxicity and long term toxicity tests of FSK prove that the present invention is safe, the dosage of an adult is 10-120 mg every day, and the administration methods comprise oral administration, injection and spraying. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112843044-A |
| priorityDate | 2014-03-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
| Predicate | Subject |
|---|---|
| isDiscussedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396823 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID47936 |
Total number of triples: 24.